Novo Nordisk AS
(HAM:NOVA)
€
41.8
-0.20 (-0.48%)
Market Cap: 185.04 Bil
Enterprise Value: 201.74 Bil
PE Ratio: 11.60
PB Ratio: 6.95
GF Score: 81/100 
Novo Nordisk A/S Virtual R&D Investor Call (Q&A) Transcript
Jun 19, 2020 / 02:00PM GMT
Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board
/- -
Welcome back to the Novo Nordisk virtual R&D investor presentation. Now we're on to the Q&A session. (Operator Instructions)
And then I will orchestrate the meeting from here.
Questions & Answers
Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board
/- -
(Operator Instructions) So we're ready to take the first question. And the first question goes to Martin Parkhøi from Danske Bank.
Martin ParkhÃ;i;S
Danske Bank A;Research Division - Senior Equity Analyst
¸ - / -
As Karsten said, it's Martin Parkhøi from Danske Bank. Firstly, I think is focused on the obesity mass. I guess, the Phase I trial that was in a loose combination. Could you talk a bit about the device for later-stage trials? We know it needs to be a dual-chamber device, but
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers